Published in Cancer Weekly, November 26th, 2002
Peregrine's VTA technology is based on targeting agents that specifically target tumor blood vessels.
The targeting agents can be attached to therapeutic agents that destroy or occlude tumor blood vessels, leading to an avalanche of tumor cell death without harming the vasculature of normal tissue.
The new patent extends the company's broad patent coverage of VTA compositions and treatment methods by providing a unique "targeting agent- therapeutic agent" combination. The targeting agent...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.